Copyright
©The Author(s) 2017.
World J Gastroenterol. May 14, 2017; 23(18): 3367-3373
Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3367
Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3367
Table 1 Demographic, clinical characteristics, eradication rates per intention-to-treat, compliance and adverse events of patients in each therapeutics group
Dual H. pylori - resistance | Triple H. pylori- resistance | |||
C + M | C + L | M + L | C + M + L | |
OAL-10 | OAM-10 | OAC-10 | OAR-10 | |
(43) | (12) | (13) | (12) | |
Gender (females) | 70% | 67% | 69% | 67% |
Age (yr) | ||||
Mean | 51.6 | 52.8 | 50 | 53.3 |
Median (range) | 51 (18-76) | 52 (24-76) | 50 (31-75) | 53 (42-77) |
Indication | ||||
Dyspepsia | 95% | 83% | 84% | 75% |
Ulcer | 5% | 17% | 16% | 25% |
ITT eradication | 42/43 (97.6%) | 11/12 (91.6%) | 12/13 (92.3%) | 7/12 (58.3%) |
Compliance | 93% | 93% | 93% | 94% |
Adverse events | 22% | 25% | 23% | 17% |
- Citation: Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373
- URL: https://www.wjgnet.com/1007-9327/full/v23/i18/3367.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i18.3367